Orexo: Zubsolv July prescription Data

Research Update

2017-08-04

17:06

The market share (rolling 4 weeks average) for Zubsolv was slightly lower in July compared to last month (June). Tablets market share reached 5.34% (5.44%) at the end of July, and TRx reached a market share of 5.18% (5.27%). As previously communicated from Orexo, as of the 1st of July Zubsolv no longer has an exclusivity position in Maryland, FFS Medicaid. This probably is the most significant reason for the market share decline in July. The overall market for buprenorphine/naloxone based opioid addiction treatments continued to show an accelerating growth rate in July. The y/y growth rate was 12.5% (11.2%) (TRx) and 11.8% (10.3%)(quantity), on a monthly basis, at the end of July.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.